Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low Dose Inotuzumab Ozogamicin in R/R CD22+ ALL
NCT03094611Phase 2Terminated
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Nov 2017
- Primary completion
- Mar 2020
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of inotuzumab ozogamicin in acute lymphoblastic leukemia (ALL), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Complete Remission at 2 years. Started Nov 2017; status: terminated.
02
Drugs
inotuzumab ozogamicin
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT03094611.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03094611.